Bioniz Therapeutics Raises $13M In Funding Round

Irvine-based Bioniz Therapeutics, a company developing biopharmaceuticals aimed at treating immuno-inflammatory diseases and cancer, has raised $13M in a Series A funding. The funding was co-led by Takeda Ventures and former Allergan CEO Dr. David Pyott, and also included Mr. Joe Kiani (CEO of Masimo), and Cota Capital. As part of the funding, Pyott, Ilan Zipkin of Takeda Ventures and Kiani have all joined the company's board of directors. Bioniz said its biopharmaceutical efforts are aimed the discovery and development of first-in-class peptide therapeutics that selectively and simultaneously inhibit multiple cytokines to treat immuno-inflammatory diseases and cancer. More information »